Description: 3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and Dana"Farber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
Home Page: www.3sbio.com
No. 3 A1, Road 10
Shenyang,
110027
China
Phone:
86 24 2538 6000
Officers
| Name | Title |
|---|---|
| Dr. Jing Lou M.D., Ph.D. | Co-Founder, Exec. Chairman, CEO & Pres |
| Dr. Dongmei Su | Sr. VP & Exec. Director |
| Mr. Fei Wang | Chief Financial Officer |
| Ms. Lu Xia | Director of Investor Relations |
| Ms. Hui Dang | Director of Risk and Compliance Management |
| Mr. Thomas Folinsbee C.F.A., CFA | Director of Corp. Devel. |
| Mr. Xin Ma | VP of the HR Department |
| Ms. Siu Kuen Lai FCIS, FCS | Company Sec. |
| Ms. Fei You | Director of the Fin. Department & Financial Controller |
| Mr. Junlin Wang | Pres of Guojian |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 13.0208 |
|---|---|
| Trailing PE: | 11.3067 |
| Price-to-Book MRQ: | 1.5367 |
| Price-to-Sales TTM: | 3.126 |
| IPO Date: | 2007-02-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 5160 |